



Practitioner's Docket No. U 014293-3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Yuhpyng L. CHEN**

Serial No.: 09/580,791

Group No.: 1614

Filed: May 30, 2000

Examiner.: Dwayne C. Jones

For: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

ATTENTION: GROUP DIRECTOR

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT AFTER
MAILING DATE OF FINAL ACTION OR NOTICE OF ALLOWANCE
BUT BEFORE PAYMENT OF ISSUE FEE (37 C.F.R. 1.97(d))**

NOTE: 37 C.F.R. 1.97: "(d) An information disclosure statement shall be considered by the Office if filed by the applicant after the period specified in paragraph (c) of this section [i.e., after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application], provided that the information disclosure statement is filed on or before payment of the issue fee and is accompanied by:

- (1) *The statement specified in paragraph (e) of this section; and*
- (2) *The fee set forth in § 1.17(p)."*

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.

37 C.F.R. 1.10*

- ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature _____

Date: December 18, 2003

CLIFFORD J. MASS
(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: If the information disclosure statement that contains the items required by 37 C.F.R. 1.97(d) is filed before, or simultaneously with, the payment of the issue fee, then it will be considered. See Notice of April 20, 1992 (1138 O.G. 37-41, 40) and 37 C.F.R. 1.97(d).

12/31/2003 AMWDAF1 00000016 09580791

03 FC:1806

180.00 OP

(Transmittal of Information Disclosure Statement after Mailing Date of Final Action or Notice of Allowance But before
Payment of Issue Fee—page 1 of 3) 6-5

**TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

WARNING: *"A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).*

STATEMENT, PETITION AND FEE

2. In accordance with the requirements of 37 C.F.R. 1.97(d):
- A. Accompanying this transmittal is a statement, as specified in 37 C.F.R. 1.97(e).
 - B. Applicant hereby petitions for the consideration of the accompanying information disclosure statement. 37 C.F.R. 1.97(d)(2).
 - C. Applicant submits the petition fee set forth in § 1.17(p) (\$180.00).

NOTE: *"The petition should be directed to the Group Director of the examining group handling the application. The petition need do nothing more than request consideration of the information being submitted." Notice of April 20, 1992 (1138 O.G. 37-41, 40).*

FEE DUE

3. Petition fee due (§ 1.17(i)): \$180.00

METHOD OF PAYMENT OF FEE

- 4.
- ☒ Attached is a check for \$180.00.
 - ☐ Charge Account _____ \$180.00.
A duplicate of this petition is attached.

If any additional petition fees are due, please charge Account 12-0425.

Reg. No. 30,086

Tel. No. (212) 708-1890

Customer No.: 00140



SIGNATURE OF PRACTITIONER

CLIFFORD J. MASS

(type or print name of practitioner)

P.O. Address

c/o Ladas & Parry
26 West 61st Street
New York, N.Y. 10023



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yuhpyng L. CHEN
Serial No.: 09/580,791 Group No.: 1614
Filed: May 30, 2000 Examiner.: Dwayne C. Jones
For: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Attorney Docket No.: U 014293-3

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the references listed on the attached Form PTO-1449. Copies of the references are also attached.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.

37 C.F.R. 1.10*

- ☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: December 18, 2003


Signature

CLIFFORD J. MASS

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Respectfully submitted,



CLIFFORD J. MASS
LADAS & PARRY
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.30,086(212)708-1890

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 014293-3

09/580,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

May 30, 2000

1614

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AR	Delta Sleep-Inducing Peptide Response to Human Corticotropin-Releasing Hormone (CRH) in Major Depressive Disordr, 1998 Soc. Biol. Psychiatry - Lesch, Widerlov, Ekman, Laux, Schulte, Pfuller, Beckman
AS	Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders, Endocrinology and Metabolism Clinics of N.A. 31 (2002) 15-36 - Vgontzas, Chrousos
AT	Antidepressant-like effects of CP-154,526, a selective CRF ₁ receptor antagonist, European Journal of Pharmacology 323 (1997) 21-26, Mansback, Brooks, Chen

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 014293-3

90/580,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

May 30, 2000

1614

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AR	CP-154,526: A potent & selective nonpeptide antagonist of corticotropin releasing fctr receptors, Proc. Natl Acad Sci. Vol. 93, pp 10477-10482, Sept 1996 Pharmacology - Shultz, Mansbach, Sprouse, Braselton, Collins, Corman, Dunaikis, Faraci, Schmidt, Seeger, Seymour, Tingley, Winston, Chen, Heym
AS	Corticotropin-releasing hormone microinfusion in central anygdala diminishes a cardiac parasympathetic outflow undr stress-free conditns, Brain Research 625(1993)219-227pp27-35- Bohus, Koolhaas
AT	Interactions between Testicular Serotonergic, Catecholaminergic, and Corticotropin-Releasing Hormone Systems Modulating cAMP and Testosterone Production in the Golden Hamster, Neuroendocrinology 2002:76:35-46- Frungieri, Zitta, Pignataro, Gonzalez-Calvar, Calandra

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.


SERIAL NO.

U 014293-3

09/580,791

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

May 30, 2000

1614

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AR	The Role of the CRH Type 1 Rcptr in Autonomic Responses to Corticotropin-Releasing Hormone in the Rat, Neuropsychopharmacology 2000-vol.22,no.4- Nijsen,Croiset,Stam,Bruijnzeel,Diamant,Wied,Wiegant
AS	Dble-blnd, randomized trl for the cntl of delayed emesis in pnts receiving cisplatin: Comparison of placebo vs. adrenocorticotrophic hormone (ACTH), Anls of Oncology3:481-485 1992- Passalacque, Cocconi, Bella,Monici,Michiara,Bandini,Bacchi
AT	Dble-Blnd, Multicenter, Randomized Trial to Cmpre the Effect of 2 Dses of Adrenocorticotrophic Hormone Vs Placebo in Controlling Delayed Emesis After High-Dose Cisplatin in Adult Patients with Cancer, Journal of Clinical Oncology, Vol 15, No 6(June) 1997 pp 2467-2473 - Passalacqua, Cocconi, Caminiti, Silingordi, Bella, Bichisao, Michiara, Malavasi, Donati, Di Costanzo, Rocca, Sarra, Scaglione, Fraschini

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

SERIAL NO.

U 014293-3

09/580,791

APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

May 30, 2000

1614

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AR	Hormonal Responses of Metoclopramide- Treated Subjects experiencing Nausea or emesis During Parabolic Flight, Aviation, Space and Environmental Medicine, September 1987- Kohl
	AS	
	AT	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.